Sign in

SLXN on Nasdaq

Silexion Therapeutics Corp

Biological products company based in George Town, Cayman Islands2

In its 2026 annual report the company says: “We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog.”5 Its shares trade on Nasdaq under the symbol SLXN.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerSLXN on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersGeorge Town, Cayman Islands2
  • Incorporated inCayman Islands3
  • Business address12 Abba Hillel Road, Ramat Gan, L3 52506063
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI254900063EP9AZODNJ852
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressC/O Conyers Trust Company (Cayman) Limited, KY1-1111 George Town, Cayman Islands2
  • Registered withGeneral Registry, MC-4085262

See how the biggest companies compare on our leaderboards

We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (“ KRAS ”). The KRAS gene, when mutated, plays a central role in many cancer types, such as pancreatic, colorectal and lung, and is therefore considered to be an oncogene. This oncogene instructs cells to make the corresponding KRAS protein which has a controlling function in cell growth signaling in the cancer cells. While multiple pharmaceutical companies are pursuing strategies to inhibit or tag the KRAS protein for degradation and thereby limit its downstream signaling, our approach is differentiated by targeting the root cause of oncogenic signaling— we silence the KRAS oncogene itself, preventing the production of the oncogenic protein.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income67-$11.6M in 2025+148% since 2023
-$15.0M-$10.0M-$5.0M02023: -$4.7M-$4.7M20232024: -$12.6M-$12.6M2024+169%2025: -$11.6M-$11.6M2025−7%
Net income67-$11.9M in 2025+133% since 2023
-$20.0M-$15.0M-$10.0M-$5.0M02023: -$5.1M-$5.1M20232024: -$16.5M-$16.5M2024+223%2025: -$11.9M-$11.9M2025−28%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development (including $0 and $1,796 from related party, for the year ended December 31, 2025 and December 31, 2024, respectively)$7.1M$5.8M
General and administrative (including $134 and $2,972 from related party, for the years ended December 31, 2025 and December 31, 2024, respectively)$4.5M$6.8M
TOTAL OPERATING EXPENSES$11.6M$12.6M
OPERATING LOSS$11.6M$12.6M
Financial expenses (income), net (including $232 and $(1,249) from related party, for the years ended December 31, 2025 and December 31, 2024, respectively)$277.0K$3.9M
LOSS BEFORE INCOME TAX$11.9M$16.5M
INCOME TAX$3.0K$10.0K
NET LOSS FOR THE YEAR$11.9M$16.5M
Equity holders of the Company$11.9M$16.4M
Non-controlling interests$0$76.0K
LOSS PER ORDINARY SHARE, BASIC$8.96$394.94
LOSS PER ORDINARY SHARE, DILUTED$8.96$394.94
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE1.3M shares41.6K shares
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE1.3M shares41.6K shares

Compare Silexion Therapeutics Corp with another company

Corporate structure

Silexion Therapeutics Corp sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Silexion Therapeutics Corp

  • Silexion Therapeutics Corp George Town, Cayman Islands
    • Moringa Acquisition Corp Subsidiary · Cayman Islands
    • Silenseed (China) Ltd. Subsidiary · China

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Silexion Therapeutics Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$108.0K7 Dec 31, 2025$99.0K7 Dec 31, 2024+9.1%
Accumulated depreciation$83.0K7 Dec 31, 2025$69.0K7 Dec 31, 2024+20.3%
Property and equipment, net$25.0K7 Dec 31, 2025$30.0K7 Dec 31, 2024−16.7%
Operating-lease assets (leased space)$412.0K7 Dec 31, 2025$530.0K7 Dec 31, 2024−22.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.0M7 Dec 31, 2025$1.2M7 Dec 31, 2024+404.7%

Properties, in its own words

We currently lease 464 square meters of office space at 12 Abba Hillel Silver Road, Ramat Gan, Israel. The lease term is for 24 months, which began on November 1, 2024 and will end on October 31, 2026, with an option for us to extend for an additional 24 months ending October 31, 2028. Monthly rent payments, including utilities, amount to approximately $14,558 per month.

Item 2 of the 10-K filed Mar 17, 2026.5

Leadership

Who has led Silexion Therapeutics Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ilan Hadar2024–now

Chair

  1. Ilan Hadar2024–now

Chief financial officer

  1. Hadar Mirit Horenshtein2024–now
2025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerMirit Horenshtein-Hadar named Aug 11, 202520

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Moringa Acquisition Corp Cayman Islands4
  • Silenseed (China) Ltd. China4
  • Silexion Therapeutics GmbH Germany4
  • Silexion Therapeutics Ltd. Israel4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Biomotion SciencesMay 9, 2024 to Aug 15, 20243

Timeline

  1. Sep 30, 20268-K Regulation FD disclosure21
  2. Sep 29, 20268-K Entered a material agreement; Unregistered sale of shares; Other events22
  3. Sep 28, 20268-K Regulation FD disclosure23
  4. Sep 25, 20268-K Shareholder vote24
  5. Sep 25, 20268-K Listing notice or transfer25
  6. Aug 21, 20268-K Listing notice or transfer26
  7. Aug 14, 20268-K Results of operations27
  8. Aug 13, 20268-K Entered a material agreement; Other events28
  9. Aug 13, 20268-K Other events29
  10. Aug 10, 20268-K Regulation FD disclosure30
  11. Aug 4, 20268-K Regulation FD disclosure31
  12. Aug 3, 20268-K Other events32
  13. Aug 15, 2024New chief executive Ilan Hadar becomes CEO10
  14. Apr 2, 2024Founded Silexion Therapeutics Corp is founded2

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($28.80) a share, on Nov 12, 2025.33

When it reported results

  1. Aug 14, 2026Reported quarterly or annual results27
  2. May 18, 2026Reported quarterly or annual results34
  3. Nov 12, 2025Reported quarterly or annual results35
  4. Aug 12, 2025Reported quarterly or annual results36
  5. May 13, 2025Reported quarterly or annual results37
  6. Mar 18, 2025Reported quarterly or annual results38
  7. Jan 14, 2025Reported quarterly or annual results39
  8. Nov 14, 2024Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

276 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 82 major events, 29 insider forms, 24 large holders, 1 private raises, 130 other. The latest 20:

  1. Oct 5, 2026DEF 14A EDGAR
  2. Sep 30, 20268-K EDGAR
  3. Sep 29, 2026424B3 EDGAR
  4. Sep 29, 20268-K EDGAR
  5. Sep 28, 2026SCHEDULE 13D/A EDGAR
  6. Sep 28, 20268-K EDGAR
  7. Sep 25, 20268-K EDGAR
  8. Sep 25, 2026PRE 14A EDGAR
  9. Sep 25, 20268-K EDGAR
  10. Sep 16, 2026DEFA14A EDGAR
  11. Sep 9, 2026DEFA14A EDGAR
  12. Aug 24, 2026DEF 14A EDGAR
  13. Aug 21, 20268-K EDGAR
  14. Aug 19, 2026SCHEDULE 13D/A EDGAR
  15. Aug 18, 2026SCHEDULE 13G EDGAR
  16. Aug 14, 2026PRE 14A EDGAR
  17. Aug 14, 202610-Q EDGAR
  18. Aug 14, 20268-K EDGAR
  19. Aug 13, 2026SCHEDULE 13G/A EDGAR
  20. Aug 13, 20268-K EDGAR

The 276 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 26, 2026Shirvan MitchellCSO and CDOSale22,818$1.36$31.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$3.6M 2025–2025
Money received by yearMoney received by year, 2025–2025: $3.6M in all. Private raises (Form D) $3.6M.$0$1M$2M$3M$4M2025 · Private raises (Form D): $3.6M2025
Figures by year
YearPrivate raises (Form D)Total
2025$3.6M$3.6M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Aug 1, 2025Raised $3.6 million in a private offering of equity20 Form D: 11 investors so far Form D

SEC filer profile

How Silexion Therapeutics Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSilexion Therapeutics Corp1
  • CIK0002022416
  • Employer ID (EIN)00-00000005
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inCayman Islands5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address12 Abba Hillel Road, Ramat Gan, L3 52506061
  • Phone972-8-62860051
  • Shares outstanding5,560,256 as of Aug 13, 20269
  • Public float$0 as of Jun 30, 202550
  • AuditorKesselman & Kesselman, Tel-Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMay 9, 20241
  • Filings276 in all: 8-K (81), 424B3 (26), 4 (18), EFFECT (15), CORRESP (14), 3 (11), UPLOAD (10), DEFA14A (9)1
    All 32 form types

    DEF 14A (8), PRE 14A (8), SCHEDULE 13G (8), 10-Q (7), POS AM (7), S-1 (7), SCHEDULE 13G/A (7), SCHEDULE 13D/A (6), S-1/A (4), S-8 (4), 424B4 (3), S-3 (3), S-4/A (3), SC 13D (3), 10-K (2), 425 (2), AW (2), DRS (2), 10-K/A (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 17, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Oct 5, 2026
    Latest 8-K (8-K) Sep 30, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, par value $0.0135 per shareSLXNThe Nasdaq Stock Market LLC
Warrants exercisable for ordinary shares at an exercise price of $1,552.50 per shareSLXNWThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 17, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Silexion Therapeutics Corp names in Item 1A of its 10-K filed Mar 17, 2026: 57 risks under these headings, as written.5

  • Risks Related to Our Financial Condition and Capital Requirements
  • We are a development-stage company and have a limited operating history on which to assess our business. We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
  • We have never generated any revenue from product sales and may never be profitable.
  • We will need to raise substantial additional funding before we can expect to become profitable from product sales. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our product development efforts or other operations.
  • Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.”
  • The historical financial results included in this Annual Report may not be indicative of what our future financial position or results of operations may be.
  • Risks Related to the Research and Development of Our Product Candidates
  • The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
  • We are heavily dependent on the success of our product candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of preclinical activity or earlier studies may not be predictive of future study results.
  • We may find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.
The other 47 risks
  • Our product candidates and the administration of our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • Even if we obtain regulatory approval for a product candidate, the related product will remain subject to regulatory scrutiny.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • We and our collaborators are subject to significant regulation with respect to manufacturing our product candidates. The facilities we subcontract to for manufacturing may not meet regulatory requirements and may have limited capacity.
  • We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.
  • Risks Related to Our Reliance on Third Parties
  • We rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates, and our business could be substantially harmed.
  • We currently rely on third parties to manufacture the raw materials and products that we use to create our product candidates and to supply us with the medical devices used to administer such product candidates. This reliance requires us to share our trade secrets with these third parties, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • Our reliance on third parties to manufacture the raw materials and products that are used to create our product candidates and to supply us with the medical devices used to administer such product candidates might cause our business harm if manufacturers fail to provide us with sufficient quantities of these materials and products or fail to do so at acceptable quality levels or prices.
  • Risks Related to Commercialization of Our Product Candidates
  • If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because some of the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market share to maintain profitability and growth.
  • We do not have experience producing our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce product candidates at the quality, quantities, locations, and timing needed to support commercialization. Additionally, we intend to rely on third-party manufacturers to produce the raw materials and products that we use to manufacture our product candidates, but we have not entered into binding agreements with any such manufacturers to support commercialization.
  • We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.
  • We currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.
  • The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.
  • The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.
  • Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
  • Our product candidates may be approved and/or commercialized only in part, only as neoadjuvant therapy, or as an adjuvant therapy.
  • Risks Related to Competition
  • The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop.
  • We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar or in the same field as ours. If these companies develop drugs more rapidly than us, or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.
  • We may not have sufficient patent terms to effectively protect our products and business.
  • Patent law, policy, or rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patent.
  • If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.
  • Intellectual property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses could be costly or not available on commercially reasonable terms.
  • Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our current patent applications or future patents, which could be expensive, time consuming, and unsuccessful.
  • We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • We may be subject to claims challenging the inventorship of our current patent application or future patents and other intellectual property.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Risks Related to Our Human Resources
  • The loss of the services of our key personnel would negatively affect our business.
  • We may be unable to attract, develop and retain additional employees required for our development and future success.
  • Risks Related to Our Operations
  • Our business and operations, or those of our CROs or third parties, may suffer in the event of computer system failures, cyberattacks or deficiencies in our cybersecurity, which could materially affect our results.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products.
  • We may not be able to successfully identify and execute strategic alliances or other relationships with third parties or to successfully manage the impacts of acquisitions, dispositions or relationships on our operations.
  • Risks Related to our Operations in Israel
  • Conditions in the Middle East and in Israel may harm our operations.
  • It may be difficult to enforce a U.S. judgment against us, our officers or our directors or to assert U.S. securities law claims in Israel.
  • Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective of their agreements with us, which in turn could impact our future profitability.
  • Risks Related to Ownership of Our Ordinary Shares
  • If we fail to maintain compliance with Nasdaq continued listing requirements, our shares may be delisted from the Nasdaq Capital Market.
  • The price of our ordinary shares and our warrants may be volatile, and the value of our ordinary shares and our warrants may decline.
  • A substantial number of our ordinary shares may be issued pursuant to the ATM Agreement and/or the conversion terms of the A&R Sponsor Promissory Note, which could cause (i) the price of the ordinary shares to decline, and (ii) substantial dilution to our existing shareholders.
  • The ordinary shares (including ordinary shares underlying warrants) that are being offered by selling securityholders under registration statements that we currently have in effect represent a substantial percentage of our outstanding ordinary shares, and the sale of such shares, or the perception that such sales may occur, could cause the price of our ordinary shares to be more volatile or decrease.
  • Because we have no current plans to pay cash dividends on our ordinary shares for the foreseeable future, you may not receive any return on investment unless you sell Silexion ordinary shares for a price greater than that which you paid for it.
  • To the extent we need to effect an additional reverse share split, our ordinary shares may experience extreme price volatility unrelated to our actual or expected performance, making it difficult for investors to assess the value of our ordinary shares.
  • We qualify as an “emerging growth company” as well as a “smaller reporting company” within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, it could make our securities less attractive to investors and may make it more difficult to compare our performance to the performance of other public companies.
  • Risks Related to U.S. Federal Income Taxation
  • The PFIC status of our company could result in adverse U.S. federal income tax consequences to U.S. Holders.
  • If a U.S. person is treated as owning at least 10% of the shares of our company, such person may be subject to adverse U.S. federal income tax consequences.
  • General Risks
  • We may be subject to securities litigation, which is expensive and could divert management attention, including securities class action and derivative lawsuits which could result in substantial costs.

Legal proceedings

To the knowledge of our management, there is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50